These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Clinical significance of immunoglobulin A antibody to hepatitis B core antigen of polymeric and monomeric forms in chronic type B liver disease with acute exacerbation.
    Author: Nomura M, Douchin M, Tokuda A, Sato F, Ito S, Kohli Y, Fujiki N.
    Journal: Am J Gastroenterol; 1988 Dec; 83(12):1390-4. PubMed ID: 3195545.
    Abstract:
    Serum immunoglobulin A (IgA) hepatitis B core antibody (anti-HBc) was measured by a solid-phase enzyme immunoassay using monoclonal antibodies in sera from chronic carriers of hepatitis B surface antigen (HBsAg). To reinforce the clinical significance of IgA anti-HBc, levels of IgA subclasses and molecular characterization of IgA anti-HBc in sera of 13 patients in the acute exacerbation phase and the remission phase were compared. IgA anti-HBc was significantly higher in sera in the acute exacerbation phase than in the remission phase (p less than 0.025); in particular, more significant changes were observed in IgA2 anti-HBc (p less than 0.0025) and in secretory IgA anti-HBc (p less than 0.001). Analysis of molecular size distribution of IgA anti-HBc by high performance liquid chromatography showed that the elevation of polymeric IgA anti-HBc was significantly greater than that of monomeric IgA anti-HBc in the acute exacerbation phase (p less than 0.05), although there was an increase in both monomeric and polymeric IgA anti-HBc. Thus, the elevation of polymeric IgA anti-HBc suggests that the focal immune response against HBcAg in the liver and secretory IgA anti-HBc is an important marker of acute exacerbation in patients with HBsAg-positive chronic liver disease.
    [Abstract] [Full Text] [Related] [New Search]